ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0251

A Comparative Study of the Validity of the DAS28-ESR and JADAS-27 Disease Activity Assessment Indexes for Juvenile Idiopathic Arthritis in Transition and Adults

Takako Miyamae1, Eiichi Tanaka1, Eisuke Inoue2, Katsunori Ikari1 and Masayoshi Harigai3, 1Tokyo Women's Medical University, Tokyo, Japan, 2Showa University, Tokyo, Japan, 3Tokyo Women's Medical University School of Medicine, Tokyo, Japan

Meeting: ACR Convergence 2021

Keywords: Juvenile idiopathic arthritis, Measurement Instrument, medical transition

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 6, 2021

Title: Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)

Session Type: Poster Session A

Session Time: 8:30AM-10:30AM

Background/Purpose: The 2020 Rheumatoid Arthritis Clinical Practice Guidelines by the Ministry of Health, Labour, and Welfare Research Group recommends the JADAS27 as a measure of disease activity in transitional and adult JIA, reflecting the characteristics of JIA-affected joint localization, and citing the possibility of underestimation by the DAS28. We compared the validity of DAS28-ESR and JADAS27 in transitional and adult JIA.

Methods: Patients aged 18 years or older at the time of the study with an onset of younger than 18 years were selected from the prospective observational studies of IORRA conducted by the Institute of Rheumatology, Tokyo Women’s Medical University.

Results: A total of 3,528 cases (age 39.1(SD 15.1) years at the survey, 13.5 (SD 3.8) years of onset, 25.6 (SD 16.0) years of disease duration) were included in the study. Activity according to both disease activity indices in order of high, medium, low disease activity and remission were DAS28-ESR (mean 2.9, SD 1.3):5.5%, 31.7%, 19.5%, 43.3%, JADAS27 (mean 7.6 , SD 6.3): 65.2%, 16.3%, 7.8%, 10.7%, and JADAS 27 and JADAS 27 presented a higher disease activity configuration than DAS28-ESR. The high frequency of active joints was 23.0% in the hands and 12.4% in the elbows. JADAS27-specific joints were active in the ankle (11.3%), neck (2.6%), and hips (1.2%), and in 686 cases (19.4%) with these joints, the DAS28-ESR mean of 2.8 (SD 1.3) and the JADAS27 mean of 7.3 (SD 6.5) was not underestimated by the DAS28-ESR compared to the whole subject.

Conclusion: JADAS27 has been applied to the severity classification of articular JIA as the designated incurable disease in Japan and is socially important in transitional and adult JIA, but it is necessary to recognize the difference between the JADAS27 and the DAS28-ESR in its application.


Disclosures: T. Miyamae, None; E. Tanaka, AbbVie Japan GK, 6, Asahi Kasei Corp., 6, Astellas Pharma Inc., 6, Ayumi Pharmaceutical Co., 6, Chugai Pharmaceutical Co., Ltd., 6, Eisai Co., Ltd., 6, Eli Lilly Japan K.K., 6, GlaxoSmithKline K.K., 6, Bristol Myers Squibb, 6, Kyowa Pharma Chemical CO., Ltd., 6, Janssen Pharmaceutical K.K., 6, Mochida Pharmaceutical CO., Ltd., 6, Pfizer Japan Inc., 6, Takeda Pharmaceutical Co., Ltd., 6, Teijin Pharma Ltd., 6; E. Inoue, Pfizer, 6, Bristol-Myers Squibb, 6, Nippontect systems, 1; K. Ikari, Asahi Kasei Pharma Co., 6, Astellas Pharma Inc., 6, AbbVie Japan GK, 6, Ayumi Pharmaceutical Corporation, 6, Bristol Myers Squibb Co., Ltd., 6, Chugai Pharmaceutical Co., Ltd., 6, Eisai Co., Ltd., 6, Eli Lilly Japan K.K., 6, Janssen Pharmaceutical K.K., 6, Kaken Pharmaceutical Co. Ltd., 6, Mitsubishi Tanabe Pharma Co., 6, Pfizer Japan Inc., 6, Takeda Pharmaceutical Co. Ltd., 6, Teijin Pharma Ltd, 6, UCB Japan Co. Ltd., 6, Ayumi Pharmaceutical Corporation, 5, Chugai Pharmaceutical Co., Ltd., 5, Mitsubishi Tanabe Pharma Co., 5, Mochida Pharmaceutical Co., Ltd., 6, Nippon Kayaku Co., Ltd., 5, Teijin Pharma Ltd., 5; M. Harigai, None.

To cite this abstract in AMA style:

Miyamae T, Tanaka E, Inoue E, Ikari K, Harigai M. A Comparative Study of the Validity of the DAS28-ESR and JADAS-27 Disease Activity Assessment Indexes for Juvenile Idiopathic Arthritis in Transition and Adults [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/a-comparative-study-of-the-validity-of-the-das28-esr-and-jadas-27-disease-activity-assessment-indexes-for-juvenile-idiopathic-arthritis-in-transition-and-adults/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-comparative-study-of-the-validity-of-the-das28-esr-and-jadas-27-disease-activity-assessment-indexes-for-juvenile-idiopathic-arthritis-in-transition-and-adults/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology